MissionIR Articles
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Forecasts $75M in GAAP Revenue Over Next 6 Months, Implements Immediate Measures to Cut Overall Expenses
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it expects to ramp up its commercial sales to a monthly average of $12.5 million. As a result, the company forecasts $75 million in estimated GAAP revenue over the next six months from both Mullen Commercial’s and its subsidiary Bollinger Motors’ sales…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reports 6791% QoQ Revenue Growth, Continued Decrease in Monthly Cash Burn
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced expectations to report a significant revenue increase for the quarter ended September 30, 2024. The company anticipates recording approximately $4.5 million in revenue in the just-ended quarter, compared to $65,235.00 in the previous quarter ended June 30, 2024, a quarter-over-quarter increase of 6791%.…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary, Clene Nanomedicine Inc., has closed on a registered direct offering and concurrent private placements. According to the announcement, the transactions consist of common stock and warrants and were with…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), Japan Tobacco Inc. Announce Planned Partnership to Leverage Quantum Computing, AI in Drug Discovery
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) announced plans to partner on a joint proof-of-concept project to explore the use of quantum computing technology and artificial intelligence (“AI”) to accelerate the speed and quality of the drug discovery…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Shares Video Update from CEO
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today shared a video update to shareholders provided by CEO and Chairman David Michery. In the video, Michery provides a detailed overview of the company’s recent progress, including sales and distribution expansion and financial performance. According to the update, the company’s sales activities with existing…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Partnership with Staque to Accelerate Commercial Adoption of Quantum in the Middle East
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has announced its partnership with Staque, a leading consulting and development practice with a focus on artificial intelligence (“AI”), blockchain and quantum computing. According to the announcement, the two companies will…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta,…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product,…
-
MissionIRNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Reports on Voting Held During Annual Meeting of Stockholders
NextPlat (NASDAQ: NXPL), a global e-commerce provider, has released the voting results from its Special Annual Meeting of Stockholders, which was held Sept. 13, 2024. According to the report, shareholder voted on six agenda items, including a proposal to approve and adopt the merger agreement and plan of reorganization making Progressive Care Inc. (OTCQB: RXMD)…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Gains ‘Strong Foothold’ in California’s Central Valley on Newly Named Dealer
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that its subsidiary, Bollinger Motors, has added Affinity Truck Center, a family-owned business founded in 1980, to its retail network. As a result, Affinity, which operates sales locations in Bakersfield and Fresno, California, as well as service locations in Paso Robles and Salinas,…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Industry Expert as New CFO
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has named a seasoned medtech leader as its new chief financial officer. According to the announcement, Timothy Cruickshank has accepted the role of chief financial officer, effective immediately; he succeeds Richard Brounstein, who announced his retirement. Cruickshank…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Closes $7.4M Registered Direct as Company Targets Cash Flow Positive in Q1 2026
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study
- MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures First Missouri Contract as PureSecurity Platform Displaces Incumbent Provider
- Safe & Green Holdings Corp. (NASDAQ: SGBX) Sets December 29 Annual Meeting as It Advances Energy Strategy and Finalizes Olenox–Safe & Green Merger
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Highlights Operational Progress Following $20 Million in Strategic Investments